drugset / Trial / NCT05257590
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
Timeline
- Start
- 2022-05-23
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVM-1118 | Small molecule | 200 mg | Oral |
| Subject | CVM-1118 | Small molecule | 300 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |